The death toll from Lassa fever in Nigeria has risen to 53 according to the latest situation report of the disease obtained from the NCDC on Thursday.

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

The Nigeria Centre for Disease Control and Prevention has recorded 214 confirmed cases of Lassa fever, and 39 deaths from December 30, 2024, to January 19, 2025, in 10 states across 43 local ...

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing next generation immunotherapeutics based on its proprietary arenavirus platform. The company ...

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The Nigeria Centre for Disease Control and Prevention has confirmed 143 cases of Lassa fever out of the 484 suspected cases from December 30, 2024, to January 12, 2025, in seven states across 32 local ...

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel immunotherapies through its arenavirus platform for cancer and chronic infectious diseases using its ...